Skip to main content

Table 1 Demographics and clinical features of overall cohort for patients with vs. without cancer a

From: Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma

Characteristics

 

Cancer subgroups

No cancer (n = 2,023)

Total (N = 154)

Breast (n = 65)

Lung (n = 16)

Haemato (n = 19)

GI (n = 17)

GU (n = 6)

Gynae (n = 17)

Skin (n = 6)

Sex

Female, n (%)

1,663 (82.2)

131 (85.1)

65 (100)

12 (75)

14 (73.7)

13 (76.5)

2 (33.3)

17 (100)

3 (50)

Male, n (%)

360 (17.8)

23 (14.9)

NA

4 (25)

5 (26.3)

4 (23.5)

4 (66.7)

NA

3 (50)

SSc/cancer onset

Median age (±SD) at SSc onset, years

45 (±14.1)

53 (±11.9)

53 (±11.1)

47 (±19.5)

51.5 (±9.4)

53 (±11.4)

59 (±18.4)

53 (±23.7)

59.5 (±19.1)

IQR = 35 to 55

IQR = 43 to 58

IQR = 44 to 58

IQR = 41 to 54

IQR = 44 to 56

IQR = 45 to 60

IQR39 to 68

IQR = 35 to 57

IQR = 46 to 63

Cancer prior to SSc onset (median ± SD), months

No cancer

39.5 (±81.6)

36 (±77.3)

NA

109 (±88.2)

8.5 (±27.7)

25 (±74.4)

141 (±104.8)

NA

IQR = 12 to 125

IQR = 11 to 114

IQR = 29 to 190

IQR = 1 to 48

IQR = 4

IQR = 25 to 243

Cancer after SSc onset, (median ± SD), months

No cancer

119 (±95.3)

108 (±108.5)

125 (±93.8)

101 (±73.4)

168 (±90.6)

116.5 (±79.9)

137 (±91.9)

62 (±55.5)

IQR = 41 to 185

IQR = 25 to 209

IQR = 71 to 200

IQR = 20 to 161

IQR = 119 to 233

IQR = 60

IQR = 20 to 194

IQR = 23 to 125

SSc subsets

dcSSc, n (%)

657 (32.5)

53 (34.4)

22 (33.8)

5 (31.3)

8 (42.1)

4 (23.5)

2 (33.3)

4 (23.5)

3 (50)

lcSSc, n (%)

1,260 (62.3)

98 (63.6)

42 (64.6)

11 (68.8)

11 (57.9)

12 (70.6)

3 (50)

13 (76.5)

3 (50)

Missing cases, n (%)

106 (5.2)

3 (1.9)

1 (1.5)

0 (0)

0 (0)

1 (5.9)

1 (16.7)

0 (0)

0 (0)

SSc autoantibody status

ACA, n (%)

550 (27.2)

40 (26)

17 (26.2)

2 (12.5)

4 (21.1)

8 (47.1)

1 (16.7)

6 (35.3)

1 (16.7)

Scl to 70, n (%)

416 (20.6)

28 (18.2)

10 (15.4)

5 (31.3)

5 (26.3)

1 (5.9)

1 (16.7)

4 (23.5)

1 (16.7)

RNAP, n (%)

247 (12.2)

41 (26.6)

19 (29.2)

4 (25)

5 (26.3)

3 (17.6)

2 (33.3)

3 (17.6)

3 (50)

Others, n (%)

515 (25.4)

31 (20)

13 (19.9)

3 (18.9)

4 (21)

3 (17.6)

1 (16.7)

4 (23.6)

1 (16.7)

ANA-negative, n (%)

75 (3.7)

9 (5.8)

4 (6.2)

0 (0)

1 (5.3)

2 (11.8)

1 (16.7)

0 (0)

0 (0)

Missing cases, n (%)

220 (10.9)

5 (3.2)

2 (3.1)

2 (12.5)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

Organ involvementb

Lung fibrosis, n (%)

NA

52 (33.8)

24 (36.9)

8 (50)

6 (31.6)

4 (23.5)

3 (33.3)

2 (11.8)

2 (33.3)

PAH, n (%)

NA

27 (17.5)

15 (23.1)

1 (6.3)

3 (15.8)

3 (17.6)

0 (0)

2 (11.8)

1 (16.7)

GI, n (%)

NA

85 (55.2)

35 (53.8)

9 (56.3)

12 (63.2)

9 (52.9)

1 (16.7)

10 (58.8)

3 (50)

SRC, n (%)

NA

16 (10.4)

4 (6.2)

1 (6.3)

2 (10.5)

4 (23.5)

1 (16.7)

2 (11.8)

0 (0)

  1. aACA, Anticentromere antibody; ANA, Antinuclear antibody; dcSSc, Diffuse cutaneous systemic sclerosis; GI, Gastrointestinal; GU, Genitourinary; Gynae, Gynaecological; Haemato, Haematological; IQR, Interquartile range; lcSSc, Limited cutaneous systemic sclerosis; NA, Not applicable; PAH, Pulmonary arterial hypertension; RNAP, RNA polymerase III; SRC, Scleroderma renal crisis; SSc, Systemic sclerosis. Cohort sample populations comprised 154 SSc patients with cancer and 2,023 SSc patients without cancer. bExtent and pattern of organ involvement is defined in the Methods section.